Endo International said today it will eliminate 90 full-time positions in a restructuring designed to lower costs, increase efficiencyand bring the company back into the black following recent losses and a plunge in its stock price.
Endo said its restructuring would primarily affect its corporate and branded pharmaceutical R&D operations at its U.S. headquarters in Malvern, PA, as well as in Chestnut Ridge, NY, where Par Pharmaceutical was headquartered until it was acquired by Endo in 2015.
The restructuring, Endo said, was intended to better align those operations with its recently restructured Generics and U.S Branded Pharmaceutical business segments.
Endo acknowledged that it will incur approx…
Read the full article at: http://www.genengnews.com/gen-news-highlights/endo-axing-90-employees-in-restructuring/81253776